Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CyPep-1
i
Other names:
CyPep-1, CY-101
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Cytovation
Drug class:
Immunomodulator, Axin2 activator
Related drugs:
‹
hydroxychloroquine (7)
quaratusugene ozeplasmid (3)
CMP-001 (3)
Orca-T (1)
SQZ-AAC-HPV (1)
SV-102 (1)
MAM-06.301 (1)
ABV-1501 (0)
ALT-801 (0)
ATA520 (0)
HLA-matched donor mononuclear enriched leukocytes (0)
BMS-986242 (0)
CEP-37250 (0)
CK0801 (0)
CO-1002 (0)
rimiducid activated rivogenlecleucel (0)
GB221 (trastuzumab biosimilar) (0)
GSK2302024A (0)
Ganfule (0)
IL-17E (0)
IMCnyeso (0)
KFA115 (0)
MVA-BN-HER2 (0)
NOV-002 (0)
84AA-API 14AA (0)
nelipepimut-S (0)
ORB-011 (0)
engineered donor allograft cell therapy (0)
parvovirus H-1 (0)
FT1050+FT4145 programmed mPB (0)
allodepleted T-cell immunotherapeutics (0)
SER-401 (0)
SI-101 (0)
ScTIL (0)
ScTIL210 (0)
TAEK-VAC-HerBy vaccine (0)
TAK-012 (0)
TST010 (0)
Undisclosed CISH inactivated TIL (0)
alpha-tocopheroloxyacetic acid (0)
WTX212 (0)
SB-313 (0)
thymalfasin (0)
BAZE-X1 (0)
chlorogenic acid (0)
dendritic cell activation therapy (0)
DVX101 (0)
hV01 (0)
minocycline (0)
EC-18 (0)
HF1K16 (0)
oral rhLF (0)
hydroxychloroquine (7)
quaratusugene ozeplasmid (3)
CMP-001 (3)
Orca-T (1)
SQZ-AAC-HPV (1)
SV-102 (1)
MAM-06.301 (1)
ABV-1501 (0)
ALT-801 (0)
ATA520 (0)
HLA-matched donor mononuclear enriched leukocytes (0)
BMS-986242 (0)
CEP-37250 (0)
CK0801 (0)
CO-1002 (0)
rimiducid activated rivogenlecleucel (0)
GB221 (trastuzumab biosimilar) (0)
GSK2302024A (0)
Ganfule (0)
IL-17E (0)
IMCnyeso (0)
KFA115 (0)
MVA-BN-HER2 (0)
NOV-002 (0)
84AA-API 14AA (0)
nelipepimut-S (0)
ORB-011 (0)
engineered donor allograft cell therapy (0)
parvovirus H-1 (0)
FT1050+FT4145 programmed mPB (0)
allodepleted T-cell immunotherapeutics (0)
SER-401 (0)
SI-101 (0)
ScTIL (0)
ScTIL210 (0)
TAEK-VAC-HerBy vaccine (0)
TAK-012 (0)
TST010 (0)
Undisclosed CISH inactivated TIL (0)
alpha-tocopheroloxyacetic acid (0)
WTX212 (0)
SB-313 (0)
thymalfasin (0)
BAZE-X1 (0)
chlorogenic acid (0)
dendritic cell activation therapy (0)
DVX101 (0)
hV01 (0)
minocycline (0)
EC-18 (0)
HF1K16 (0)
oral rhLF (0)
›
Associations
News
Trials
Filter by
Latest
3ms
Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
P1/2, N=6, Completed, Cytovation AS | Active, not recruiting --> Completed | N=90 --> 6 | Trial completion date: Feb 2025 --> Sep 2024
3 months ago
Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
5ms
CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
P1/2, N=60, Completed, Cytovation AS | Active, not recruiting --> Completed | Trial primary completion date: Mar 2024 --> Jul 2024
5 months ago
Trial completion • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
Keytruda (pembrolizumab) • CyPep-1
12ms
Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
P1/2, N=90, Active, not recruiting, Cytovation AS
12 months ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
1year
Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
P1/2, N=90, Active, not recruiting, Cytovation AS | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2
1 year ago
Enrollment closed • Phase classification • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
over1year
CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
P1/2, N=75, Active, not recruiting, Cytovation AS | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
over 1 year ago
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
almost2years
Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
P1b/2a, N=90, Recruiting, Cytovation AS | Not yet recruiting --> Recruiting
almost 2 years ago
Enrollment open • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
over2years
A study to evaluate the safety and efficacy of CyPep-1 in combination with Pembrolizumab for the treatment of advanced or metastatic cancers. (clinicaltrialsregister.eu)
P1/2, N=90, Ongoing, Cytovation ASA
over 2 years ago
New P1/2 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • CyPep-1
over2years
CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
P1/2, N=75, Recruiting, Cytovation AS | N=45 --> 75 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
over 2 years ago
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • CyPep-1
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login